Acute Bacterial Skin and Skin Structure Infections Market Projections Reveal Dynamic Growth in Asia Pacific Region Amid Global Rise to USD 2.31 Billion by 2034

Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Acute Bacterial Skin and Skin Structure Infections Market by Type of Infection, Route of Administration, Distribution Channel, and By Region" report has been added to * ResearchAndMarkets.com's* offering.

The healthcare industry observes a substantial growth in the acute bacterial skin and skin structure infections (ABSSSI) market, revealing the latest analysis which predicts a notable climb from USD 1.34 billion to an estimable USD 2.31 billion by 2034.

This trend reflects a Compound Annual Growth Rate (CAGR) of 5.12% over the forecast period of 2024 to 2034. The report highlights the escalating occurrences of ABSSSI worldwide.

Observing the segmentation by type of infection, community-acquired ABSSSIs have particularly shown dominant market values, attributed to an increase in skin infections within community environments.

Correspondingly, the hospital-acquired segment marks an anticipated accelerated growth trajectory, stimulated by the rise in healthcare-associated infections. From the perspective of route of administration, oral medications dominate the current market, praised for their convenience and compliance. Progress in oral antibiotic formulations is fueling this trend.

Conversely, the parenteral segment is projected to witness rapid growth due to rising critical cases requiring immediate and targeted intervention. As for distribution channels, hospital pharmacies continue to hold the lion's share in terms of revenue generation, coinciding with the strategic positions of hospitals in managing severe ABSSSI cases.

Nevertheless, retail pharmacies are expected to expand swiftly, with outpatient care of ABSSSI and the significance of accessible healthcare services casting a favorable impact. The document sheds light on the regional disparities within the market.

North America takes precedence with the highest revenue share, while the Asia Pacific region is foreseen to experience the most significant expansion, showcasing impressive CAGR figures.

Developing healthcare infrastructure and escalating healthcare awareness are pivotal in driving this regional market surge. Within this comprehensive analysis of the ABSSSI market, attention has also been given to hospital-acquired and community-acquired infections, examining their intricacies and the therapeutic nuances of both oral and parenteral administration routes. The empirical data delineates the progression and expected advancements in the treatment of these infections over the next decade.

*Significant Market Players and Regional Highlights*

The report also encompasses detailed profiles of leading market influencers, scrutinizing their operational strategies and contributions to the sector. By evaluating such entities, the report provides a 360-degree view of the market landscape and the agents that shape it.

· North America, with its established healthcare systems and diligent research endeavors, remains at the forefront of market revenue within the ABSSSI landscape.
· Asia Pacific is rapidly becoming a focal point for market growth due to increased incidences of infections and a mounting awareness of healthcare services.
· Innovations in antibiotic treatments, including oral and parenteral solutions, are essential determinants in the market's evolvement.*Key Attributes:*
*Report Attribute* *Details*
No. of Pages 200
Forecast Period 2023 - 2034
Estimated Market Value (USD) in 2023 $1.34 Billion
Forecasted Market Value (USD) by 2034 $2.31 Billion
Compound Annual Growth Rate 5.1%
Regions Covered Global

*Report Scope:*

· Base Year: 2023
· Forecast Period: 2024-2034
· Study Coverage
· Market Forecast by Type of Infection, Route of Administration, and Distribution Channel
· Market Forecast for 5 Regions and 17+ Countries

· North America (U.S. and Canada)
· Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
· Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
· Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
· MEA (South Africa, GCC, Rest of MEA)

· Company Profiles of the Top 10+ Major Market Players

*Report Segmentation*

*By Type of Infection*

· Hospital-acquired ABSSI
· Community-acquired ABSSI

*By Route of Administration*

· Oral
· Parenteral
· Topical

*By Distribution Channel*

· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies

*Companies Profiled*

· Pfizer
· Merck
· GlaxoSmithKline
· Novartis
· Allergan
· Johnson & Johnson
· Bristol Myers Squibb
· Cubist Pharmaceuticals
· Teva Pharmaceutical Industries
· Melinta Therapeutics
· F. Hoffmann-La Roche Ltd.
· Cempra
· Sun Pharmaceutical Industries Ltd.
· Actavis
· Daiichi Sankyo Company

For more information about this report visit https://www.researchandmarkets.com/r/rglrr7

*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

*Attachment*

· Global Acute Bacterial Skin and Skin Structure Infections Market

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900